期刊
CHEMICAL SCIENCE
卷 6, 期 9, 页码 5120-5127出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4sc03599b
关键词
-
资金
- New Zealand Ministry of Science and Innovation [C08X0808]
- Genesis Oncology Trust [GOT-1352-RPG]
- New Zealand Health Research Council [14-500]
- New Zealand Ministry of Business, Innovation & Employment (MBIE) [C08X0808] Funding Source: New Zealand Ministry of Business, Innovation & Employment (MBIE)
It is known that T cells can eliminate tumour cells through recognition of unique or aberrantly expressed antigens presented as peptide epitopes by major histocompatibility complex (MHC) molecules on the tumour cell surface. With recent advances in defining tumour-associated antigens, it should now be possible to devise therapeutic vaccines that expand specific populations of anti-tumour T cells. However there remains a need to develop simpler efficacious synthetic vaccines that possess clinical utility. We present here the synthesis and analysis of vaccines based on conjugation of MHC-binding peptide epitopes to alpha-galactosylceramide, a glycolipid presented by the nonpolymorphic antigen-presenting molecule CD1d to provoke the stimulatory activity of type I natural killer T (NKT) cells. The chemical design incorporates an enzymatically cleavable linker that effects controlled release of the active components in vivo. Chemical and biological analysis of different linkages with different enzymatic targets enabled selection of a synthetic vaccine construct with potent therapeutic anti-tumour activity in mice, and marked in vitro activity in human blood.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据